Home Featured Page 296

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Field Trip Health Announces Upsize to Previously Announced Bought Deal Public...

Psychedelic Business News Spotlight: February 26, 2021

California State Senator Introduces Bill to Decriminalize Psychedelics

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

PTSF48 – Decriminalization, Embracing the Mystical, and a Plea for More...

Field Trip Health Announces $50 Million Bought Deal Offering of Common...

Massachusetts Legislators Introduce Bills to Study Psychedelics, Remove Criminal Penalties

The Sober Curious: Living Alcohol-Free Is Psychedelic

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks...

PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.